What is the Best Course of Action Following PPROM Between 24 and 37 Weeks?
This study by Bond et al. (Cochrane Database Systematic Review, 2017) compared planned early birth vs. expectant management following preterm pre-labor rupture of the membranes (PPROM) between 24 and 37 weeks gestation.
Systematic Review and meta-analysis
This update of a 2010 Cochrane review included 12 randomized controlled trials, with analyses on a total of 3,617 women and 3,628 infants.
There was no significant difference in rates of neonatal sepsis or proven neonatal infection
Early birth was associated with
Increased rate of RDS (Relative Risk 1.26, 95% CI 1.05 to 1.53)
Increased rate of c-section (Relative Risk 1.26, 95% CI 1.11 to 1.44)
There was no significant difference in rates of overall perinatal mortality or intrauterine deaths between the two groups
Early birth was associated with the following maternal outcomes
Decreased rate of chorioamnionitis (Relative Risk 0.50, 95% CI 0.26 to 0.95)
Decreased hospital stay with a mean difference of -1.75 days (95% CI -2.45 to -1.05)
Increased rate of endometritis (Relative Risk 1.61, 95% CI 1.00 to 2.59)
Early birth was associated with the following neonatal outcomes
Higher rates of neonatal death (Relative Risk 1.26, 95% CI 1.11 to 1.44)
Higher rates of ventilation (Relative Risk 1.27, 95% CI 1.02 to 1.58)
Delivery at lower gestational ages with a mean difference of -0.48 weeks (95% CI -0.57 to -0.39)
Higher rates of NICU admission (Relative Risk 1.16, 95% CI 1.08 to 1.24)
Improved maternal and infant outcomes in expectant management greater than 34 weeks gestation for RDS and maternal infections
Antibiotics reduce maternal infections in the expectant management group
If there are no contraindications, overall the expectant management group with careful monitoring had better outcomes for mother and baby
Further research needed for subgroup analysis as to who would not benefit from expectant management
Long term neurodevelopment was not addressed in this study
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan